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ORIGINAL ARTICLE
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Abstract
A dynamic, properly organised actin cytoskeleton is critical for the production and haemostatic
function of platelets. The Wiskott Aldrich Syndrome protein (WASp) and Actin-Related Proteins 2 &
3 Complex (Arp2/3 complex) are critical mediators of actin polymerisation and organisation in
many cell types. In platelets and megakaryocytes, these proteins have been shown to be important
for proper platelet production and function. The cortactin family of proteins (Cttn & HS1) are
known to regulate WASp-Arp2/3-mediated actin polymerisation in other cell types and so here we
address the role of these proteins in platelets using knockout mouse models.
We generated mice lacking Cttn and HS1 in the megakaryocyte/platelet lineage. These mice
had normal platelet production, with platelet number, size and surface receptor profile
comparable to controls. Platelet function was also unaffected by loss of Cttn/HS1 with no
differences observed in a range of platelet function assays including aggregation, secretion,
spreading, clot retraction or tyrosine phosphorylation. No effect on tail bleeding time or in
thrombosis models was observed. In addition, platelet actin nodules, and megakaryocyte
podosomes, actin-based structures known to be dependent on WASp and the Arp2/3 complex,
formed normally. We conclude that despite the importance of WASp and the Arp2/3 complex
in regulating F-actin dynamics in many cells types, the role of cortactin in their regulation
appears to be fulfilled by other proteins in platelets.
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Introduction
The actin cytoskeleton plays a critical role in both the production of
platelets from megakaryocytes [1] and in the proper functioning of
platelets [2]. Several proteins, which are either part of the cytoske-
leton or regulate its organisation (including mDia1, WASp, Myosin,
profilin and ADF/Cofilin), have been shown to be important for
producing sufficient platelets of the correct size [3–9]. Similarly,
many cytoskeletal proteins have been shown to be required for
proper platelet function including Filamin A, WASp, myosin, and
α-actinin [5,10–12]. Two actin-related structures which have been
identified in platelets and megakaryocytes are the actin nodule and
the podosome, respectively [7,13]. Recent studies have shown that
podosomes, and the subsequent degradation of extracellular matrix,
are required for proplatelet protrusion through the basement mem-
brane of the blood vessel during the later stages of platelet formation
[14], and that actin nodules are platelet podosome-like structures
which contribute to platelet aggregate stability under flow [11]. Both
of these structures are dependent on WASp-Arp2/3-mediated actin
polymerisation for proper formation [7,11,13,14]. Furthermore, the
Arp2/3 complex is regulated by a number of different proteins
including the cortactin (Cttn) family of proteins (Cttn & haemato-
poietic lineage cell-specific protein 1 (HS1)) [15].
Cttn is an F-actin binding protein which can interact with the
actin nucleation promoting factor, the Arp2/3 complex and stabilise
dynamic branched actin networks. In addition, it can act as a
scaffolding protein due to its ability to interact with a wide range
of molecules (Reviewed in [15–17]). It is a target for both kinases
and acetylases, post-translational modifications which regulate its
F-actin binding activity and subsequent role in dynamic actin
processes. Cttn is ubiquitously expressed, however, in haemato-
poietic cells its homologue HS1 is the major form. Osteoclasts
and megakaryocytes/platelets are unusual in that both forms are
expressed [18] and their expression has been shown to increase
during megakaryocyte maturation [19]. In addition, Cttn has been
reported to be robustly phosphorylated in human platelets follow-
ing activation [20–23]. Studies where Cttn expression has been
knocked out in mouse embryonic fibroblasts have produced
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conflicting results showing either no effect on actin dynamic and
cell motility or a reduction in these processes [24,25]. Several
studies have shown that Cttn can regulate the formation of podo-
somes and invadopodia (reviewed in [17]) and that loss of Cttn
reduces the invasiveness of cancer cells through reduction in inva-
dopodia formation and ECM degradation [26]. We have previously
shown that platelets deficient in HS1 are indistinguishable from
controls [27], although Kahner et al. [28] showed a small reduction
in platelet function. Furthermore, recent evidence suggests that
Cttn affects proplatelet production in human megakaryocytes, but
in mice, megakaryocyte development and proplatelet formation is
unaffected by loss of Cttn (unpublished data). Thus, Cttn may have
a minor role in megakaryocyte and platelet dynamics, but this is
likely to be redundant with other proteins for most purposes.
To address whether Cttn and the related protein HS1 showed
redundancy, we generated a megakaryocyte/platelet specific gene
knockout mouse (Cttn KO) which we crossed with the HS1
knockout mouse to generate Cttn/HS1 double knockouts (DKO).
Here, we present evidence that loss of both Cttn and HS1 shows
no detectable phenotype in platelets, suggesting further redun-
dancy in the system and calling into question reports on the
essential nature of the Cttn-related proteins in cell dynamics.
Methods
Generation of a Cttn/HS1 double knockout mouse
HS1 knockout mice were generated and genotyped as described
previously [27,29]. Conditional Cttn knockout mice were gener-
ated by Taconic (Koeln, Germany) (Supplementary Figure 1A, B,
C). Conditional Cttn mice were crossed with the PF4-Cre recom-
binase (PF4-Cre) expressing mouse line [30] and the HS1 knock-
out mice to generate either platelet-specific Cttn knockout mice
(Cttn KO) or platelet-specific Cttn and constitutive HS1 knockout
mice (DKO). Wildtype mice (WT) were either conditional Cttn
mice which expressed no PF4-Cre recombinase, or PF4-Cre posi-
tive mice which lacked the floxed Cttn allele. Genotyping of mice
was carried out by PCR on genomic DNA extracted from ear
clippings taken at three weeks after birth. Primers PF4Cre-R (5′-
TGCACAGTCAGCAGGTT-3′) and Pf4Cre-F (5′-
CCCATACAGCACACCTTTTG-3′) were used to identify mice
containing the PF4-Cre recombinase (~400 bp fragment). For
Cttn, WT and floxed alleles were identified using forward and
reverse primers (5′-TCATCAAGATCGGTGGTTCC-3′ & 5′-
CAGTGATGGACTTAGAAGCTGG-3′, respectively) to generate
284 bp WT or 441 bp floxed PCR fragments (Supplementary
Figure 1D). Western blotting confirmed loss of protein expression
in mouse platelets (Supplementary Figure 1E). The genotypes
used in this study are indicated in Supplemental Figure 1F. All
animals were maintained using housing and husbandry in accor-
dance with local and national legal regulations.
Preparation of mouse platelets
Blood was drawn from CO2 terminally-narcosed mice under
anaesthesia from the vena cava and taken into ACD at a ratio
of 1:10 for washed platelets or, for studies performed in
platelet-rich plasma (PRP), into sodium citrate. Platelet num-
bers in whole blood were determined using an ABX Micros
60 (ABX Diagnostics, Montpelier, France). PRP and washed
platelets were prepared as previously described [31].
DIC and fluorescence microscopy of spread platelets
Coverslips were incubated with a suspension of fibrinogen
(100 μg mL−1) or collagen-related peptide (CRP, 100 μg
mL−1) overnight at 4°C. Surfaces were washed and then
blocked with denatured BSA (5 mg mL−1) for 1 h at room
temperature followed by subsequent washing with PBS before
use in spreading assays. Platelets (2 x 107 mL−1) were
allowed to spread on immobilized proteins for 45 min at 37°
C. Surfaces were then washed with PBS to remove non-
adherent cells before fixation with 10% formalin (4% paraf-
ormaldehyde), for 10 min at room temperature. Platelet mor-
phology was imaged as previously described [31]. The
platelet surface area of spread platelets was computed using
Fiji software package (http://fiji.sc/#). For actin staining:
fixed, spread platelets were permeabilised with 0.1% Triton
X-100 in PBS for 5 min, washed 3x in PBS and then stained
with 488-phalloidin (1 in 500) for 60 mins before imaging.
Platelet aggregation studies
Platelet aggregation was monitored using 300 μL of 2 x 108 mL–1
of washed platelets. Stimulation of platelets was performed in a
Chrono-Log aggregometer (Chrono-Log, Havertown, PA, USA)
with continuous stirring at 1200 rpm at 37 °C as previously
Figure 1. Characterisation of platelets from Cttn KO and DKO mice. (A)
Western blots of platelet lysates confirming phosphorylation of Cttn down-
stream of G-protein coupled and tyrosine kinase linked receptors. Cortactin
was immuno-precipitated from stimulated mouse platelet lysates and western
blottedwith anti-phosphotyrosine (4G10) and anti-cortactin (4F11) antibodies.
(B) Whole blood platelet counts and mean platelet volumes were measured
from WT, Cttn and DKO mice. No significant difference was observed
between the genotypes in either platelet number or volume. Data is mean ±
SD (WT, n= 37; Cttn KO, n= 24; DKO, n=18). (C) Platelet surface receptor
levels were analysed by flow cytometry. No significant differences were
observed between either genotype andWTcontrols. Data are % ofWTcontrol
(Mean ± SEM; n= 3) and values were corrected for IgG background staining.
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described [32]. ATP secretion was also determined during aggre-
gation using Chronolume reagent.
Flow cytometry studies
Surface receptor levels on washed platelets were determined
using anti-mouse antibodies (Emfret) against αIIbβ3 (clone
LeoF2), GP1b (clone Xia.H10), α2 (clone SAMC1) and
GPVI (clone JAQ1). P-Selectin expression, phosphatidylserine
exposure and fibrinogen binding were determined using anti-
P-Seletin (Emfret, clone Wug.Eg), Annexin-V-PE (BD
Biosciences) and 488-Fibrinogen (Invitrogen), respectively.
Samples were analysed using an Accuri C6 flow cytometer
(BD Biosciences).
Clot retraction assays
Whole murine blood was anti-coagulated with sodium citrate
and PRP prepared as above. The platelet count was adjusted to
3 × 108 /ml with HEPES-Tyrodes containing CaCl2 (2 mM)
and fibrinogen (2 mg/ml). 400 μl of this mix was placed into an
aggregometer tube and incubated at 37°C for 5 min. 2 μl of
mouse erythrocytes were added for colour contrast. Thrombin
(10 U/ml) was added and mixed with a paper-clip and clot
retraction was allowed to proceed at 37°C for 1 hour with the
paper-clip present. At appropriate time points, the clot was
pulled out with the paper-clip and the remaining serum volume
measured. These experiments were performed blind.
Tail bleed assays
Experiments were conducted on 20–35 g male and female WT
(n = 18), Cttn KO (n = 12) and DKO (n = 7) mice. Mice were
anaesthetized with isofluorane via a face mask throughout the
experiment and subsequently injected with the analgesic bupre-
norphine (ip). The terminal 3 mm of tail was removed using a
sharp razor blade and blood was collected. Mice were allowed to
bleed until they lost either 15% blood volume or for 20 min.
Data were presented as the weight of blood lost (mg).
In vitro flow studies
For in vitro flow studies, mouse blood was prepared and treated
as described by Calaminus et al. [31]. Platelet adhesion results are
expressed as the percentage of surface area covered by platelets.
Laser injury thrombosis model
The ability of Cttn KO mice to undergo normal thrombosis was
tested using the laser injury model as previously described [33].
Megakaryocyte podosome formation
Bone marrow megakaryocytes were isolated and allowed to spread
on fibrinogen coated coverslips for 3 hrs as previously described
[34], prior to staining with 488-phalloidin and anti-vinculin.
Data analysis
Results are shown as mean ± SEM from at least three experi-
ments unless otherwise stated. Statistical comparisons were made
using ANOVA or Student’s test as appropriate using Graphpad
Prism 6.
Results and discussion
Generation of knockout mice
Cttn has been reported to be robustly phosphorylated in
human platelets following activation [20–23] and we con-
firmed that Cttn was also phosphorylated in mouse platelets
downstream of both tyrosine kinase linked and G protein-
coupled receptors (Figure 1A). We had previously demon-
strated that genetic knockout of HS1 in mouse platelets has
no effect on platelet function [27]. A similar study by Kahner
et al. [28], on the same mouse model, identified a mild
bleeding defect in the HS1 knockout mice. We hypothesised
that the absence of a significant phenotype in these mice may
be due to the expression of the second family member, Cttn in
megakaryocytes and platelets [19,35]. As evidence suggested
that Cttn was important at a very early stage of oocyte devel-
opment [36], we made a conditional flox mouse. This mouse
expressed a Cttn allele where exon 5 was flanked by LoxP
sites using homologous recombination (Supplementary
Figure 1A & B). Removal of exon 5 from Cttn generates a
premature stop codon in exon 7 which results in a truncated
transcript which is predicted to undergo nonsense mediated
RNA decay (Supplementary Figure 1C). These mice were
crossed with mice expressing the megakaryocyte-specific
PF4-Cre recombinase transgene [30] to generate platelet-
and megakaryocyte-specific cortactin knockout mice (Cttn
KO) and the HS1 knockout mice to generate double Cttn/
HS1 knockout mice (DKO). Mice were genotyped using
PCR (Supplementary Figure 1D) with the genotypes of the
mice used in this study shown in Supplementary Figure 1E).
Characterisation of platelets from knockout mice
Both Cttn KO and DKO mice displayed no overt phenotype
and observation of the mice revealed no obvious defects in
development. Furthermore, knockout mice were visually undis-
tinguishable from WT or heterozygous mice. To establish that
gene disruption resulted in a loss of expression of protein,
western blots were performed confirming that expression of
Cttn and/or HS1 proteins was lost in platelets (Supplementary
Figure 1E). Whole blood platelet analysis was performed and
no difference was observed in either platelet number or volume
(Figure 1B) between WT, Cttn KO and DKO mice, indicating
that the steady-state production of platelets is not affected by
the loss of these proteins. Other haematological parameters,
including red blood cell count, haematocrit, mean corpuscular
volume and white blood cell count, were also within normal
ranges (data not shown). Furthermore, both Cttn KO and DKO
platelets had normal levels of the major platelet surface recep-
tors (αIIbβ3, α2β1, GP1b & GPVI, Figure 1C). These data
show that platelet production is normal in both Cttn KO and
DKO mice.
Platelet spreading and F-actin organisation are unaffected
by loss of Cttn and HS1
Cttn and HS1 are known to interact with F-actin and a number
of actin-binding proteins (including Arp2/3 complex, WASp,
WIP, dynamin) as well as with other signalling proteins (e.g.
Src family kinase, PTP1B & PAK) [15,16]. They are believed
to be key in organising the actin cytoskeleton and the forma-
tion of actin-rich structures including lamellipodia, actin
nodules and podosomes. Therefore, we investigated the effect
of loss of Cttn and HS1 on platelet spreading, a process
dependent on F-actin dynamics and organisation. No signifi-
cant difference was observed for either Cttn KO or DKO
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platelets compared to WT controls when spread on fibrinogen
(± thrombin) or collagen-related peptide (CRP) (Figure 2A &
B). Furthermore, Cttn KO and DKO platelets formed normal
filopodia and actin nodules during early spreading on fibrino-
gen and went onto form both lamellipodia and stress fibres
when fully spread (Figure 2C) with normal Arp2/3 localisation
(Supplementary Figure 4A & B). These data indicate that
neither protein is essential for normal platelet spreading and
highlights the redundancy present within platelets regarding
actin organisation. Furthermore, it is interesting that while
Figure 2. Loss of Cttn and HS1 does not affect platelet spreading or F-actin organisation. (A) The loss of Cttn only or Cttn and HS1 from platelets did
not affect their ability to adhere and spread on fibrinogen (±0.1 U/ml thrombin) or collagen related peptide (CRP) coated coverslips. (B) Quantitation
of the surface area of spread platelets from either Cttn KO or DKO platelets showed no significant differences in spreading. (C) Staining of spread
platelets for F-actin with fluorescent phalloidin showed normal actin organisation with filopodia, actin nodules and platelet stress fibres being observed
in both WT and DKO platelets. Scale bars in (A) = 10 µm and in (C) = 5 µm.
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both the Arp2/3 complex and WASP are required for actin
nodule formation [11], Cttn is not.
Loss of Cttn and HS1 does not affect platelet function
To fully assess the effect of genetic deletion of Cttn and HS1
on platelet function, washed platelets were tested for a num-
ber of functional responses. First, the ability of platelets to
aggregate in response to either collagen or thrombin was
monitored at both low and high doses of agonist. For both
agonists and at all doses, no significant difference was
observed between WT, Cttn KO or DKO platelets
(Figure 3A & B). The absence of an aggregation defect was
confirmed by measuring αIIbβ3 integrin activation via fluor-
escent fibrinogen binding. Data indicate that there was no
difference in integrin activation between WT, Cttn KO or
DKO platelets (Supplementary Figure 2C). Secretion of
platelet granule contents is critical for proper platelet function
and the actin cytoskeleton is important for this process [37].
To establish if there is any deficiency in granule secretion, we
monitored release of dense granules and α-granules during
platelet activation. No significant difference was observed in
the secretion of either dense granule contents (measured by
observing ATP secretion during platelet activation -
Supplementary Figure 2A & B) or in α-granule contents
(measured by observing P-selectin expression on the platelet
surface – Figure 2C) following platelet activation downstream
of tyrosine-kinase or G protein coupled receptor agonists.
Finally, signal transduction in the platelets was measured by
observing phosphotyrosine signalling downstream of collagen
activation. No difference observed between DKO and WT
platelets (Supplementary Figure 2D).
The ability of platelets to link to the coagulation cascade and
provide a pro-thrombotic surface was also investigated. The
Figure 3. Loss of Cttn and HS1 does not affect platelet function. The loss of Cttn alone or both Cttn and HS1 had no effect on the aggregation (A & B)
or α-granule secretion (C) of platelets to G-protein coupled or tyrosine kinase linked receptor agonists. Aggregation data are expressed as % final
aggregation 6 mins after agonist addition. Alpha granule secretion data are % of WT values measured by flow cytometry 2 mins after addition of
agonist. (D) The loss of Cttn and HS1 had no effect on pro-coagulant surface generation as phosphatidylserine exposure was not affected by loss of
both cortactin and HS1. (E) Clot retraction in PRP following stimulation by thrombin was unaffected by loss of Cttn or Cttn and HS1. All data are
presented as mean ± SEM, n = 3.
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expression of phosphatidylserine on the platelet surface was
unaffected by the loss of Cttn or both Cttn and HS1
(Figure 3D), and the ability of mutant platelets to drive clot
retraction was also not significantly different from controls
(Figure 3E). All together, these data indicate that although Cttn
is an important regulator of F-actin network dynamics and scaf-
folding in many cell types in vitro, it does not appear to be
required for proper platelet function.
Physiological and in vivo platelet function
To establish if mice lacking Cttn displayed impaired haemostasis, tail
bleeding time measurements were performed. Single Cttn KO mice
displayed a slightly reduced haemostatic capacity as the amount of
blood lost was increased when compared to both WT and DKO mice
(Figure 4A). However, this difference was not significant.
Furthermore, in flow aggregation experiments, no difference was
observed in surface area coverage of platelet aggregates for WT and
Cttn or DKO mice at either 1000 s−1 or 1500 s−1 (Figure 4B). In
addition, no difference in the dynamics of thrombus formation or in
time to peak intensity (Figure 4C&D)was observed in the laser injury
thrombosis model. Taken together, this data suggests that platelet Cttn
and HS1 are not required for normal haemostasis.
Podosome formation in bone marrow megakaryocytes
Cttn is implicated in the formation of podosomes and invadopodia,
actin-rich structures involved in extracellular-matrix interactions [38]
and we have previously shown that podosomes are required for proper
proplatelet protrusion across the basement membrane [14]. Bone
marrow derived megakaryocytes from WT, Cttn KO and DKO mice
spread on fibrinogen all produced podosomes with the characteristic
vinculin ring staining pattern (Supplementary Figure 3) and normal
Arp2/3 localisation (Supplementary Figure 4C&D).Megakaryocytes
from DKO mice develop normally as assessed by total MK number,
number of CFU-MKs, DNA ploidy level and are able to undergo
normal proplatelet formation and platelet release (data not shown).
Furthermore, in these mice, steady-state platelet number and size was
normal (Figure 1B) and platelet recovery following immune-induced
thrombocytopenia was also normal (data not shown). Taken together,
these data indicate that loss of Cttn and HS1 following genetic knock
out does not affectmegakaryocyte development or platelet production.
In conclusion, while Cttn is well described in the literature as a
regulator of F-actin network dynamics in several cell types and
specifically to play a role in invadopodia/podosome formation [39,
40, 41], the data presented here demonstrate that Cttn and HS1 are
redundant for function in mouse megakaryocytes and platelets. It is
possible that some of the redundancy in genetic knockouts such as
HS1 and Cttn reflects compensation following long term loss of
these proteins. Most cell biology studies of Cttn in regulation of the
actin cytoskeleton involve relatively short term siRNA knockdowns,
while we have used long term genetic knockout. It is increasingly
becoming apparent that cells and perhaps also tissues and organisms
often can compensate for loss of gene function by modification of
other pathways [42]. Timescale must also be considered when
comparing inhibitors and genetic knockouts due to potential com-
pensation mechanisms. Thus, Cttn and HS1 may play a role in
platelet and megakaryocyte function, but this may be compensated
for when they are deleted in the long term.
Not all actin organisers are redundant, however, as loss of WASp
gives a mild but measurable phenotype [11]. Shorter term, inhibi-
tion of platelet Arp2/3 complex completely blocks platelet spread-
ing and actin nodule formation [11], but this has not been tested by
genetic knockout. It would be interesting to know whether WASp,
Cttn, HS1 triple null platelets had a more severe defect than WASp
nulls, but this experiment would be technically difficult to achieve.
Figure 4. In vivo thrombosis assays and in vitro flow studies. (A) An increase in tail bleeding (mg blood loss/g body weight) was observed in Cttn
KO mice following removal of the terminal 3 mm of the tail. However, this increase was not significant and was not observed in DKO mice.
Symbols (● = WT, Δ = Cttn KO, × = DKO) represent individual data points, horizontal bars the mean and vertical bars the SEM (n = 18 for WT,
12 for Cttn KOs and 7 for DKOs). (B) In vitro flow assays performed over collagen showed no significant decrease in aggregate formation at shear
rates of either 1000 s−1 or 1500 s−1 for either Cttn KO or DKO mice. (C & D) In vivo thrombosis, as determined by the cremaster laser injury
model, showed no effect of loss of Cttn on either thrombus size (C) or time to peak intensity (D).
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Furthermore, it would be interesting to know if loss of Arp2/3
complex could be genetically compensated for, as loss of Arp2/3
in fibroblasts causes major phenotypes [42,43,44].
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